Gómez J M, Gómez N, Amat M, Biondo S, Rafecas A, Jaurrieta E, Soler J
Services of Endocrinology and Surgery. Ciutat Sanitaria i Universitaria de Bellvitge. L'Hospitalet de Llobregat, Barcelona Spain.
Ann Endocrinol (Paris). 2000 Sep;61(3):184-91.
The aim of this work was to describe late permanent hypothyroidism after iodine-131 or surgery, and to seek predictive factors of hypothyroidism for the two treatments.
From 1979 to 1994, 462 patients with Graves' disease hyperthyroidism underwent definitive treatment. Three hundred and fifty-five patients were treated with low calculated doses of iodine-131, and 107 patients with subtotal thyroidectomy. Life-table analysis was performed and the cumulative incidence of hypothyroidism was calculated by Kaplan-Meier's method, and survival (euthyroidism) within the groups was compared by the Mantel-Cox method.
Of the 355 patients treated with one dose of 6.6 1.9 mCi of iodine-131, 246 became euthyroid after one dose, and 109 needed 2 or more doses. Twenty-two patients received one or more doses higher than 10 mCi. The probability of euthyroidism at 145 months after low-dose was 10. 19% and age, sex, pretreatment with antithyroid drugs, previous subtotal surgery did not influence the final outcome. Of the 107 surgically treated patients the probability of euthyroidism at 144 months was 56.1%. Age, sex, duration of hyperthyroidism, duration of antithyroid treatment, weight of thyroid resected, did not influence the final outcome. The weight of the thyroid remnant was 5.4 1.5 g and the multivariate statistical model by conditional logistic regression showed that the weight of thyroid remnant was the only variable that influenced long-term thyroid function.
There is no ideal dose of iodine-131 that would correct hyperthyroidism in Graveś disease without risk of hypothyroidism. Surgery is an alternative definitive treatment with a risk of hypothyroidism within the 2 first years, and a cumulative risk of hypothyroidism lower than with iodine-131.
本研究旨在描述碘-131治疗或手术治疗后出现的晚期永久性甲状腺功能减退,并探寻这两种治疗方法导致甲状腺功能减退的预测因素。
1979年至1994年期间,462例格雷夫斯病甲亢患者接受了确定性治疗。355例患者接受了计算剂量较低的碘-131治疗,107例患者接受了甲状腺次全切除术。进行寿命表分析,采用Kaplan-Meier法计算甲状腺功能减退的累积发病率,并采用Mantel-Cox法比较各组内的生存情况(甲状腺功能正常)。
355例接受6.6±1.9毫居里单剂量碘-131治疗的患者中,246例单剂量治疗后甲状腺功能恢复正常,109例需要2剂或更多剂量。22例患者接受了一剂或多剂高于10毫居里的碘-131治疗。低剂量治疗后145个月时甲状腺功能恢复正常的概率为10.19%,年龄、性别、抗甲状腺药物预处理、既往甲状腺次全手术均不影响最终结果。107例接受手术治疗的患者中,144个月时甲状腺功能恢复正常的概率为56.1%。年龄、性别、甲亢病程、抗甲状腺治疗时间、切除甲状腺的重量均不影响最终结果。甲状腺残余重量为5.4±1.5克,条件逻辑回归的多变量统计模型显示,甲状腺残余重量是影响长期甲状腺功能的唯一变量。
不存在理想剂量的碘-131既能纠正格雷夫斯病甲亢又无甲状腺功能减退风险。手术是另一种确定性治疗方法,在最初两年内有甲状腺功能减退风险,且甲状腺功能减退的累积风险低于碘-131治疗。